This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

FDA Grants Type B Meeting To Be Held November 8, 2010 To Discuss Phase III Protocols For Androxal®

Repros Therapeutics Inc. ® (NasdaqCM:RPRX) today announced that the Company has been granted a Type B meeting to be held on November 8, 2010 with the Division of Reproductive and Urologic Products to review the Company’s Phase III pivotal efficacy protocols for Androxal ® in the treatment of secondary hypogonadism. Androxal is an oral drug that normalizes both testosterone and sperm levels.

The Phase III studies are designed to compare Androxal to a topical testosterone and placebo. In a similarly designed small pilot study previously conducted by Repros, only Androxal resulted in consistent normalization of both testosterone and sperm counts in a majority of subjects. In this population of men that previously used a topical testosterone, after three months of treatment, no men on testosterone or placebo exhibited normal concentrations for both measures. Per FDA recommendation, benefit will be determined by “normalization of serum testosterone levels while preserving fertility.”

The proposed Phase III efficacy program is designed to have two trials with a total of 80 subjects enrolled in each study, randomized into four 20 subject arms. The four arms are 12.5 and 25 mg Androxal, placebo and open label approved topical testosterone. The Androxal and placebo arms will be double blind. The topical testosterone will be used per manufacturers’ instructions. Subjects will be dosed for three months. The primary endpoint for the two studies is a responder analysis, with a responder being defined as an individual that exhibits a morning testosterone greater than 300 ng/dl and a total sperm count greater than 39 million sperm (or sperm concentration >15x10 6/ml) at the end of the three month dosing period. The World Health Organization Laboratory Manual for the Examination of Human Semen, 5 th Edition, has set the mean lower reference limits (5 th percentiles) for semen characteristics of fertile men at 39x10 6 total sperm per ejaculate and a concentration of 15x10 6 sperm per ml.

The two studies will recruit related but different subjects. The first study will recruit men that have been currently using a topical testosterone for at least three months. These men will be required to stop taking their current topical testosterone for three weeks. Based on one of the Company’s previously completed pilot studies, the Company believes this group of men will exhibit morning testosterone levels <250 ng/dl and sperm counts below 39x10 6 total sperm per ejaculate after the three week washout.

The second pivotal study will enroll men that are naïve to testosterone treatment or have not used topical testosterone for at least 6 months. The men will be screened to ensure that their morning testosterone is <250 ng/dl (FDA recommendation). Based on the previously completed study, the Company believes this group of men will exhibit sperm counts greater than 39x10 6 total sperm per ejaculate at baseline.

If results from previous studies are consistent with outcomes for the planned trials the Company believes the outcome from both studies will be the same. At the end of the three month dosing period only Androxal administration will result in normalization of both testosterone and sperm counts in a majority of subjects. Though these two pivotal studies for efficacy are small, Repros believes they are properly powered based on expected outcomes. The Company engaged Dr. J. Richard Trout, Professor Emeritus Rutgers, biostatistician and consultant to the pharmaceutical industry, to assess the two study designs. Based on previous experience suggesting the 12.5 mg dose of Androxal will exhibit a responder rate of 70% and topical testosterone will exhibit a responder rate of 15%, Dr. Trout opined that a study with 20 subjects per arm would be powered at the 80% level and should be more than adequate to demonstrate a statistically significant efficacy signal. Comparing the higher 25 mg dose of Androxal, which exhibited a responder rate of roughly 85% to topical testosterone, the study is powered to an even greater degree.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,790.19 +13.76 0.08%
S&P 500 1,979.92 -7.13 -0.36%
NASDAQ 4,748.3610 -32.9030 -0.69%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs